Serum fetuin-A/α2-HS-glycoprotein in human pregnancies with normal and restricted fetal growth

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 21, Issue 11, 2008, Pages 826-830

  Briana, Despina D ^a   Boutsikou, Maria ^a   Gourgiotis, Demetrios ^a   Boutsikou, Theodora ^a   Baka, Stavroula ^a   Marmarinos, Antonios ^a   Hassiakos, Demetrios ^a   Malamitsi Puchner, Ariadne ^a,b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NONE   (Greece)

Author keywords

Fetuin A; Fetus; Intrauterine growth restriction; Neonate; Pregnancy

Indexed keywords

FETUIN A; ALPHA2HS GLYCOPROTEIN; PLASMA PROTEIN;

ADULT; ARTICLE; BONE MASS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; FETUS; FETUS CIRCULATION; FETUS GROWTH; GESTATIONAL AGE; HUMAN; INTRAUTERINE GROWTH RETARDATION; MALE; METABOLIC SYNDROME X; MOTHER; NEWBORN; PERINATAL PERIOD; PLACENTAL TRANSFER; PREGNANCY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; UMBILICAL CORD; BIRTH WEIGHT; BLOOD; DELIVERY; FETUS BLOOD; METABOLISM; SEX DIFFERENCE;

ADULT; BIRTH WEIGHT; BLOOD PROTEINS; DELIVERY, OBSTETRIC; FEMALE; FETAL BLOOD; FETAL GROWTH RETARDATION; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; MALE; PREGNANCY; PROSPECTIVE STUDIES; SEX FACTORS;

EID: 56749150509     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.1080/14767050802326255     Document Type: Article

References (35)

1. Brodsky D, Christou H. Current concepts in intrauterine growth restriction. J Intensive Care Med 2004;19:307-319.
2. Namgung R, Tsang RC. Factors affecting newborn bone mineral content: in utero effects on newborn bone mineralization. Proc Nutr Soc 2000;59:55-63.
3. Barker DJ. Fetal origins of cardiovascular disease. Ann Med 1999;31:3-6.
4. Hales CN, Barker DJ. Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. Diabetologia 1992;35:595-601.
5. Terkelsen OB, Jahnen-Dechent W, Nielsen H, Moos T, Fink E, Nawratil P, Muller-Esterl W, Mollgard K. Rat fetuin: distribution of protein and mRNA in embryonic and neonatal rat tissues. Anat Embryol (Berl) 1998;197:125-133.
6. Dziegielewska KM, Matthews N, Saunders NR, Wilkinson G. alpha2HS-glycoprotein is expressed at high concentration in human fetal plasma CSF. Fetal Diagn Ther 1993;8:22-27.
7. Putnam FW. Progress in plasma proteins. In: Putnam FW, editors. The Plasma Proteins. New York, NY: Academic Press; 1984. pp 1-44.
8. Dickson IR, Poole AR, Veis A. Localization of plasma alpha2HS glycoprotein in mineralising human bone. Nature 1975;256:430-432.
9. Denecke B, Graber S, Schafer C, Heiss A, Woltje M, Jahnen-Dechent W. Tissue distribution and activity testing suggest a similar but not identical function of fetuin-B and fetuin-A. Biochem J 2003;376:135-145.
10. Dziegielewska KM, Brown WM, Deal A, Foster KA, Fry EJ, Saunders NR. The expression of fetuin in the development and maturation of the hemopoietic and immune systems. Histochem Cell Biol 1996;106:319-330.
11. Nie Z. Fetuin: its enigmatic property of growth promotion. Am J Physiol 1992;263:C551-C562.
12. Szweras M, Liu D, Partridge EA, Pawling J, Sukhu B, Clokie C, Jahnen-Dechent W, Tenenbaum HC, Swallow CJ, Grynpas MD, Dennis JW. alpha2-HS glycoprotein/fetuin - a transforming growth factor-beta/bone morphogenetic protein antagonist, regulates postnatal bone growth and remodeling. J Biol Chem 2002;277:19991-19997.
13. Mathews ST, Singh GP, Ranalletta M, Cintron VJ, Qiang X, Goustin AS, Jen KL, Charron MJ, Jahnen-Dechent W, Grunberger G. Improved insulin sensitivity and resistance to weight gain in mice null for the Ahsg gene. Diabetes 2002;51:2450-2458.
14. Lebreton JP, Joisel F, Raoult JP, Lannuzel B, Roger JP, Humbert G. Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. J Clin Invest 1979;64:1118-1129.
15. Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, Muller-Esterl W, Schinke T, Jahnen-Dechent W. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003;112:357-366.
16. Schinke T, Amendt C, Trindl A, Poschke O, Muller-Esterl W, Jahnen-Dechent W. The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis. J Biol Chem 1996;271:20789-20796.
17. Ombrellino M, Wang H, Yang H, Zhang M, Vishnubhakat J, Frazier A, Scher LA, Friedman SG, Tracey KJ. Fetuin, a negative acute phase protein, attenuates TNF synthesis and the innate inflammatory response to carrageenan. Shock 2001;15:181-185.
18. Kalabay L, Cseh K, Pajor A, Baranyi E, Csakany GM, Melczer Z, Speer G, Kovacs M, Siller G, Karadi I, Winkler G. Correlation of maternal serum fetuin/alpha2-HS-glycoprotein concentration with maternal insulin resistance and anthropometric parameters of neonates in normal pregnancy and gestational diabetes. Eur J Endocrinol 2002;147:243-248.
19. Stefan N, Hennige AM, Staiger H, Machann J, Schick F, Krober SM, Machicao F, Fritsche A, Haring HU. Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care 2006;29:853-857.
20. Fiore CE, Celotta G, Politi GG, Di Pino L, Castelli Z, Mangiafico RA, Signorelli SS, Pennisi P. Association of high alpha(2)-Heremans-Schmid glycoprotein/fetuin concentration in serum and intima-media thickness in patients with atherosclerotic vascular disease and low bone mass. Atherosclerosis 2006;195:110-115.
21. Dickson IR, Bagga M, Paterson CR. Variations in the serum concentration and urine excretion of alpha 2HS-glycoprotein - a bone-related protein, in normal individuals and in patients with osteogenesis imperfecta. Calcif Tissue Int 1983;35:16-20.
22. Gardosi J, Chang A, Kaylan B, Sahota D, Symonds EM. Customised antenatal growth charts. Lancet 1992;339:283-287.
23. Kaminopetros P, Higueras MT, Nicolaides KH. Doppler study of uterine artery blood flow: comparison of findings in the first and second trimesters of pregnancy. Fetal Diagn Ther 1991;6:58-64.
24. Acharya G, Wilsgaard T, Berntsen GK, Maltau JM, Kiserud T. Reference ranges for serial measurements of umbilical artery Doppler indices in the second half of pregnancy. Am J Obstet Gynecol 2005;192:937-944.
25. Baschat AA, Galan HL, Bhide A, Berg C, Kush ML, Oepkes D. Doppler and biophysical assessment in growth restricted fetuses: distribution of test results. Ultrasound Obstet Gynecol 2006;27:41-47.
26. Burkhardt T, Schaffer L, Schneider C, Zimmermann R, Kurmanavicious J. Reference values for the weight of freshly delivered term placentas and for placental weight-birth weight ratios. Eur J Obstet Gynecol Reprod Biol 2006;128:248-252.
27. Namgung R, Tsang RC. Bone in the pregnant mother and newborn at birth. Clin Chim Acta 2003;333:1-11.
28. Cooper C, Javaid MK, Taylor P, Walker-Bone K, Dennison E, Arden N. The fetal origins of osteoporotic fracture. Calcif Tissue Int 2002;70:391-394.
29. Harrast SD, Kalkwarf HJ. Effects of gestational age, maternal diabetes, and intrauterine growth retardation on markers of fetal bone turnover in amniotic fluid. Calcif Tissue Int 1998;62:205-258.
30. Binkert C, Demetriou M, Sukhu B, Szweras M, Tenenbaum HC, Dennis JW. Regulation of osteogenesis by fetuin. J Biol Chem 1999;274:28514-28520.
31. Colclasure GC, Lloyd WS, Lamkin M, Gonnermann W, Troxler RF, Offner GD, Burgi W, Schmid K, Nimderg RB. Human serum alpha 2HS-glycoprotein modulates in vitro bone resorption. J Clin Endocrinol Metab 1988;66:187-192.
32. Suzuki M, Shimokawa H, Takagi Y, Sasaki S. Calcium-binding properties of fetuin in fetal bovine serum. J Exp Zool 1994;270:501-507.
33. Lehtinen AB, Burdon KP, Lewis JP, Langefeld CD, Ziegler JT, Rich SS, Register TC, Carr JJ, Freedman BI, Bowden DW. Association of alpha2-Heremans-Schmid glycoprotein polymorphisms with subclinical atherosclerosis. J Clin Endocrinol Metab 2007;92:345-352.
34. Ix JH, Shlipak MG, Brandenburg VM, Ali S, Ketteler M, Whooley MA. Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation 2006;113:1760-1767.
35. Karamessinis PM, Malamitsi-Puchner A, Boutsikou T, Makridakis M, Vougas K, Fountoulakis M, Vlahou A, Chrousos G. Marked defects in the expression and glycosylation of alpha2-HS glycoprotein/fetuin-A in plasma from neonates with intrauterine growth restriction: proteomics screening and potential clinical implications. Mol Cell Proteomics 2008;7:591-599.